Lurbinectedin, a medication used in cancer treatment, poses risks during pregnancy. According to drug labeling information from the FDA, lurbinectedin can cause fetal harm when administered to a pregnant woman. It is advised that healthcare providers inform patients of the potential risks to the fetus and recommend effective contraception during treatment with lurbinectedin. Clinical trials, such as NCI-2020-09844, also highlight the importance of avoiding pregnancy while using lurbinectedin due to its potential adverse effects on the developing fetus. Therefore, it is crucial for women of childbearing age to discuss contraceptive measures with their healthcare providers before starting treatment with lurbinectedin to mitigate the risks associated with pregnancy.

Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf
[2] https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2020-09844